Dtsch Med Wochenschr 2014; 139(27): 1433-1436
DOI: 10.1055/s-0034-1370136
Prinzip & Persepektive | Review article
Nephrologie
© Georg Thieme Verlag KG Stuttgart · New York

Die membranöse Glomerulonephritis – entscheidende Fortschritte in der Diagnostik und Therapie

Membranous nephropathy – crucial developments for diagnostic and treatment
R. A. K. Stahl
1   III. Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf
,
S. Harendza
1   III. Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf
,
U. Helmchen
2   Nierenregister Hamburg, Universitätsklinikum Hamburg-Eppendorf
,
E. Hoxha
1   III. Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf
› Author Affiliations
Further Information

Publication History

11 January 2014

04 February 2014

Publication Date:
17 June 2014 (online)

 
  • Literatur

  • 1 Beck Jr LH. Membranous nephropathy and malignancy. Semin Nephrol 2010; 30: 635-644
  • 2 Beck Jr LH, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21
  • 3 Cattran D. Management of membranous nephropathy: When and what for treatment?. J Am Soc Nephrol 2005; 16: 1188-1194
  • 4 Cattran DC, Greenwood C, Ritchie S et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 1995; 47: 1130-1135
  • 5 Dähnrich C, Komorowski L, Probst C et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 2013; 421: 213-218
  • 6 Frei U, Schober-Halstenberg HJ. Bericht über Dialysebehandlung und Nierentransplantation in Deutschland 2006/2007. Berlin: QuaSi-Niere; 2008: 35
  • 7 Glassock RJ. The pathogenesis of membranous nephropathy: evolution and revolution. Curr Opin Nephrol Hypertens 2012; 21: 235-242
  • 8 Hofstra JM, Debiec H, Short CD et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1735-1743
  • 9 Hoxha E, Harendza S, Zahner G et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011; 26: 2526-2532
  • 10 Hoxha E, Kneißler U, Stege G et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 2012; 82: 797-804
  • 11 Hoxha E, Thiele I, Zahner G et al. Phospholipase A2 Receptor autoantibody levels and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 2014; im Druck
  • 12 Kerjaschki D. Pathomechanisms and molecular basis of membranous glomerulonephritis. Lancet 2004; 364: 1194-1196
  • 13 Leaf DE, Appel GB, Radhakrishnan J. Glomerular disease: why is there a dearth of high quality clinical trials?. Kidney Int 2010; 78: 337-342
  • 14 Polanco N, Gutiérrez E, Covarsí A et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21: 697-704
  • 15 Ponticelli C, Altieri P, Scolari F et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 444-450
  • 16 Qin W, Beck Jr LH, Zeng C et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011; 22: 1137-1143
  • 17 Ruggenenti P, Cravedi P, Chianca A et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1416-1425
  • 18 Stahl R, Hoxha E, Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 2010; 363: 496-498